Core Insights - The article highlights Eli Lilly's participation in the China International Import Expo, showcasing its innovative pharmaceutical products and commitment to the Chinese market [1][5][12] Product Innovations - Eli Lilly presented its new cardiovascular and metabolic health drug, Tirzepatide injection, approved for type 2 diabetes, long-term weight management, and obstructive sleep apnea [1] - The company also showcased its oral SERD Imlunestrant for breast cancer and the IL-23 inhibitor Mirikizumab for inflammatory bowel disease, both not yet approved in China [3] Public Health Initiatives - Eli Lilly created interactive experience zones, "Memory Café" and "Body Resistance Decoding Exhibition," to raise public awareness about Alzheimer's disease and obesity [3][6] - The "Body Resistance Decoding Exhibition" aims to educate the public on the physiological mechanisms behind weight management challenges, countering the stereotype that weight loss failures are due to lack of willpower [6] Strategic Collaborations - Eli Lilly announced a strategic partnership with the Shanghai Clinical Innovation and Transformation Research Institute to enhance clinical trial processes and accelerate drug development [8] - The company also established a strategic collaboration with Alibaba Health and upgraded its existing partnership with JD Health to promote digital transformation in chronic disease management [10] Investment and Market Commitment - Eli Lilly has invested over 20 billion RMB in China, emphasizing its strategic importance in the global market [11][12] - The company plans to open an innovation incubator in Shanghai and has committed to further investments, including a 1.5 billion RMB upgrade of its Suzhou factory to expand production of diabetes and obesity drugs [12]